Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AstraZeneca Pharma India Limited ( (IN:ASTRAZEN) ) has provided an announcement.
AstraZeneca Pharma India Limited has received a draft order from the Income Tax Department regarding transfer pricing issues for the assessment year 2022-23. The company plans to challenge this order before the Dispute Resolution Panel, with the quantum of the claim being approximately Rs. 11.96 crores, excluding interest and penalties. The financial implications of this draft order are yet to be determined, pending the final assessment.
More about AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates in the pharmaceutical industry, focusing on the development and commercialization of prescription medicines. The company is a part of the global AstraZeneca group, which is known for its innovative medicines across various therapeutic areas.
YTD Price Performance: 10.02%
Average Trading Volume: 1,584
Current Market Cap: 198.2B INR
For an in-depth examination of ASTRAZEN stock, go to TipRanks’ Stock Analysis page.